OBJECTIVE： To evaluate cost-effectiveness of celecoxib for osteoarthritis （OA） in China. METHODS： OA cost-effectiveness analysis model developed by National Institute for Health and Clinical Excellence （NICE） was adopted using celecoxib， diclofenac+PPIs as control. Related risk of adverse event was from CONDOR trials.The effectiveness was measured by QALY. Costs and QALYs were discounted annually at 4.76％. RESULTS： Celecoxib had a cost of $3 591 and 8.826 QALYs while diclofenac+PPIs had a cost of $3 674 and 8.830 QALYs. The incremental costs and QALYs of celecoxib to diclofenac+PPIs were －$83 and －0.004 QALYs， respectively. The incremental cost-effectiveness ratio （ICER） for diclofenac+PPIs to celecoxib was $23 258/QALY. The results of single factor sensitivity analysis and probability sensitivity analysis showed that drug cost was driving factor of ICER， and the results of two therapy plans were similar.  CONCLUSIONS： Celecoxib is a less costly alternative than diclofenac+PPIs. The difference in QALYs between celecoxib and diclofenac+PPIs is extremely small， so celecoxib is likely to be cost-effective for OA patients.